Tandem Diabetes Care (TNDM) Liabilities and Shareholders Equity (2013 - 2026)

Tandem Diabetes Care has reported Liabilities and Shareholders Equity for 14 years, with the latest figure at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 25.08% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $3.8 billion (changed 0.0% YoY), and the FY2025 full-year result was $881.1 million, down 8.94% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.2 billion, up from $881.1 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.2 billion in Q1 2026, with the low at $874.7 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $968.0 million across 5 years, with a median of $952.7 million in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 34.6% — and 2023, when it retreated 10.27%.
• Tandem Diabetes Care's Liabilities and Shareholders Equity stood at $1.1 billion in 2022, then dropped by 9.51% to $952.7 million in 2023, then grew by 1.57% to $967.7 million in 2024, then fell by 8.94% to $881.1 million in 2025, then jumped by 30.9% to $1.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.2 billion (Q1 2026), $881.1 million (Q4 2025), and $874.7 million (Q3 2025), per Business Quant data.